Patent classifications
A61K2236/39
SYSTEM AND METHOD FOR AEROBIC RESPIRATORY TREATMENT
A method of producing pure cannabidiol (CBD) isolate crystals including the steps of extracting the CBD compound from a cannabis plant; winterizing to remove fats, waxes and chlorophyll from the CBD extract; filtering the CBD extract through a series of filter plates; removing carboxylic acid and CO2 from the CBD extract; removing impurities from the CBD extract by distillation; and crystallizing the purified CBD extract to produce pure CBD isolate crystals and chopping the pure CBD isolate crystals to produce crystals of between 200 and 600 microns in size. A further embodiment includes the steps of grinding the crystals to produce micro-particles of between 1 and 5 microns and releasing the micro-particles into an air environment.
P2ET REDUCES COVID SEVERITY BY INHIBITION OF VIRAL REPLICATION, REDUCTION OF PULMONAR FIBROSIS MARKERS AND MODULATION OF INMUNE RESPONSE
The present invention provides compositions and methods for treating or prevent SARS-CoV-2 infections by delivering a therapeutically effective amount of a standardized P2Et extract enriched in polyphenol compounds from Caesalpinia spinosa that inhibits the production of coronavirus particles, reduces pulmonary fibrosis markers, down-regulates pro-inflammatory cytokines, and increases CD3+TL and CD3+CD4−CD8− T Lymphocytes subsets in COVID-19 patients. The disclosed compositions for treating or prevent SARS-CoV-2 infections comprising a standardized P2Et extract enriched in polyphenol compounds from Caesalpinia spinosa that may comprise one or more compounds selected from galloyl quinic acid and gallic acid derivatives and pharmaceutically acceptable excipients.
Ethanol extraction of psychoactive compounds from psilocybin fungus
This invention relates to the extraction of psychoactive compounds from organisms for use in medicine. Extraction is carried out with a strong acid or strong base to either promote or inhibit dephosphorylation. The extract in the slurry form is standardized with added excipient so that when it is dried the powdered composition has a specified total psychoactive alkaloid concentration, with a known ratio of phosphorylated to dephosphorylated psychoactive alkaloids.
Method to prepare a therapeutic balm
A method to prepare a therapeutic balm is disclosed. A first phase solution is prepared in an oak barrel using a grain neutral spirit. The first phase is mixed for 10 minutes per day for a month to prepare a second phase solution. The second phase solution is filtered at least twice to prepare a filtrate. The filtrate and third phase components are mixed to prepare a third phase solution. The third phase solution is mixed with a distilled wine liquor to prepare a fourth phase solution. The fourth phase solution is mixed at least twice a day for a month to prepare a fifth phase solution. The fifth phase solution is mixed with cranberry juice, pomegranate juice, and raspberry juice to prepare a sixth phase solution. The sixth phase solution is stored in a ceramic bottle for a least six months at room temperature to prepare a therapeutic balm.
Method of treating meningioma
The present invention relates to a method of treating meningioma including administering a Chinese medicine composition to a subject in need thereof; wherein the Chinese medicine composition is an extract of a first mixture comprising Coptis chinensis, Phellodendron amurense, Glycyrrhiza uralensis, Atractylodes lancea, Artemisia carvifolia, Anemarrhena asphodeloides, and Cortex Lycii.
APPLICATION OF TRADITIONAL CHINESE MEDICINE COMPOSITION TO PREPARATION OF MEDICINE FOR TREATING OR PREVENTING CORONAVIRUS INFECTION
Application of a traditional Chinese medicine composition to preparation of a medicine for treating or preventing coronavirus infection. The traditional Chinese medicine composition includes: 2-10 parts of flos lonicerae, 2-10 parts of fructus forsythiae, 2-6 parts of herba menthae, 2-4 parts of herba schizonepetae, 2-5 parts of fermented soybean, 2-6 parts of fried arctii fructus, 2-6 parts of radix platycodonis, 2-4 parts of herba lophatheri and 2-5 parts of radix glycyrrhizae. The traditional Chinese medicine composition has a good effect of treating or preventing coronavirus-related diseases.
FOOD FOR HANGOVER AND LIVER PROTECTION AND PRODUCING METHOD THEREOF
The present disclosure provides a food for hangover and liver protection and a producing method thereof. The method includes: providing the raw materials of particular percentages by weight, wherein the prepared turmeric powder accounts for 25%-35% of the provided raw materials; the prepared kudzu isoflavone powder accounts for 30%-40% of the provided raw materials; the prepared Primula sieboldii root powder accounts for 20%-30% of the provided raw materials; the prepared fruit extract accounts for 5%-14% of the provided raw materials; and the prepared vitamin complex accounts for 1%-2% of the provided raw materials; performing a sieving pretreatment on each of the provided raw materials; putting the pretreated raw materials into a wet granulator to perform a mix process for obtaining the food; and performing a testing process on the mixed food, and re-performing the mix process on the tested food in response to the tested food being unqualified.
DENDRILLA MEMBRANOSA COMPOUNDS, DERIVATIVES THEREOF, AND USES THEREOF
Described herein are Dendrilla membranosa compounds and derivatives thereof. Also described herein are formulations that can contain an amount of one or more Dendrilla membranosa compounds or derivatives thereof and a carrier. Also described herein are methods of administering one or more Dendrilla membranosa compound and/or derivative thereof or a formulation thereof to a subject in need thereof.
ANTIDEPRESSANT FOOD AND METHOD FOR PREPARING THE SAME
An antidepressant food and a method for preparing the same are provided. The antidepressant food includes, by mass percentage, Semen ziziphi spinosae powder in a range of 28% to 36%, γ-aminobutyric acid in a range of 10% to 15%, theanine in a range of 15% to 20%, phosphatidylserine in a range of 10% to 20%, Ficus tikoua extract in a range of 8% to 14%, Huperzia serrata extract in a range of 10% to 16%, sucralose in a range of 0.5% to 1% and fruit essence in a range of 0.5% to 1.5%.
Injectable psychoactive alkaloid composition and preparation thereof
The liquid composition includes a psychoactive alkaloid extract or synthetic psychoactive alkaloid. The alkaloids in the extract are predominantly dephosphorylated rather than phosphorylated. The injectable psychoactive alkaloid composition includes a carrier, an optional tonicity modifier, an optional antioxidant or preservative, an optional pH modifier, and optional further excipients. A process for obtaining an injectable psychoactive alkaloid composition includes dephosphorylating the alkaloid during extraction, purifying the extracted alkaloid, and standardizing it to a specific concentration by adding measured quantities of excipients.